From biology to treatment of monoclonal gammopathies of neurological significance
Simple Summary The peripheral nervous systems may be involved by several
hematological diseases ranging from preneoplastic diseases to overt malignancies or …
hematological diseases ranging from preneoplastic diseases to overt malignancies or …
Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed
A Fresa, I Innocenti, A Tomasso, L Stirparo, A Mosca… - Cancers, 2024 - mdpi.com
Simple Summary The treatment of chronic lymphocytic leukemia is constantly evolving.
Within the past few years, the treatment algorithm of patients with CLL has been radically …
Within the past few years, the treatment algorithm of patients with CLL has been radically …
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines …
GM Rigolin, PP Olimpieri, V Summa, S Celant… - Blood Cancer …, 2023 - nature.com
In this analysis we describe the effectiveness of first-line ibrutinib in 747 patients with chronic
lymphocytic leukemia (CLL) and TP53 aberrations in a nationwide study with a 100 …
lymphocytic leukemia (CLL) and TP53 aberrations in a nationwide study with a 100 …
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study
A Visentin, FR Mauro, G Catania, A Fresa… - Frontiers in …, 2022 - frontiersin.org
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL)
deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib …
deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib …
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia
F Perutelli, MC Montalbano, E Boccellato… - Current Opinion in …, 2022 - journals.lww.com
For the treatment of CLL, several effective therapeutic strategies to target BTK are or will
soon be available: these drugs present different safety profiles, thus making it possible to …
soon be available: these drugs present different safety profiles, thus making it possible to …
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
AR Lovell, N Jammal, P Bose - Therapeutic Advances in …, 2022 - journals.sagepub.com
Bruton's tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL). Ibrutinib …
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL). Ibrutinib …
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
A Visentin, M Puthenparampil… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Bruton's tyrosine kinase (BTK) is a multifaceted player of the immune system
which has been involved in the survival of hematological malignancies but also in the …
which has been involved in the survival of hematological malignancies but also in the …
[HTML][HTML] Frontline therapy in Chronic Lymphocytic Leukemia
M Arguello-Tomas, N Albiol, C Moreno - Acta Haematologica, 2024 - karger.com
Background: The treatment landscape of chronic lymphocytic leukemia (CLL) has
tremendously evolved in the last decades, thanks to the introduction of more effective …
tremendously evolved in the last decades, thanks to the introduction of more effective …
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis
HJJ Cherng, R Khwaja… - American journal of …, 2022 - Wiley Online Library
Long‐term follow up of prospective studies has shown that continuous Bruton's tyrosine
kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients …
kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients …
A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and …
A Visentin, MC Molinari, S Pravato, A Cellini… - Current …, 2022 - mdpi.com
Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic
leukemia (CLL) which favors the development of life-threatening infections. Subcutaneous …
leukemia (CLL) which favors the development of life-threatening infections. Subcutaneous …